Document:

EX-4.3

 Exhibit 4.3 

SECOND SUPPLEMENTAL INDENTURE 

Dated as of April 30, 2009 

between 
 HOSPIRA, INC., 

and 
 UNION BANK, N.A., 

as Successor Trustee 
 and 

BANK OF AMERICA, N.A. AS SUCCESSOR BY MERGER TO LASALLE BANK 

NATIONAL ASSOCIATION, 
 as
Resigning Trustee 
  
  

Providing for an Amendment to the Indenture 
  

 

 SECOND SUPPLEMENTAL INDENTURE, dated as of April 30, 2009, between HOSPIRA, INC., a
corporation duly organized and existing under the laws of the State of Delaware (the “Company”), having its principal office at 275 North Field Drive, Lake Forest, Illinois 60045, and UNION BANK, N.A., a national banking association duly
organized and existing under the laws of the United States of America, having its corporate trust office at 551 Madison Avenue, 11th Floor, New York, New York 10022, as successor Trustee (the “Successor Trustee”), and BANK OF AMERICA, N.A.
AS SUCCESSOR BY MERGER TO LASALLE BANK NATIONAL ASSOCIATION, a national banking association duly organized and existing under the laws of the United States of America, having its corporate trust office at 135 S. LaSalle Street, Suite 1560, Chicago,
Illinois 60603, as resigning Trustee (the “Resigning Trustee”). 
 WHEREAS, the Company and the Resigning Trustee are parties to
that certain Indenture dated as of June 14, 2004 (the “Indenture”), by and among the Issuer, as issuer, and Bank of America, N.A. as successor by merger to LaSalle Bank National Association, as trustee, as amended and supplemented
from time to time, pursuant to which the Issuer issued certain notes (the “Notes”) as listed on the attached Schedule A. 

WHEREAS, the Resigning Trustee wishes to resign as Trustee, Security Registrar and Paying Agent under the Indenture; the Issuer wishes to
appoint the Successor Trustee to succeed the Resigning Trustee as Trustee, Security Registrar and Paying Agent under the Indenture; and the Successor Trustee wishes to accept appointment as Trustee, Security Registrar and Paying Agent under the
Indenture. 
 WHEREAS, Section 9.1(8) of the Indenture provides that the Company and the Trustee together may amend or supplement the
Indenture without the consent of any Holders to add to or change any of the provisions of the Indenture as shall be necessary to provide for or facilitate the administration of the trusts thereunder by more than one Trustee, pursuant to the
requirements of Section 6.11(1); 
 WHEREAS, the Company desires to supplement the Indenture to reflect the appointment of the
Successor Trustee as the Trustee; and 
 WHEREAS, all things necessary to make the Indenture, as hereby modified, a valid agreement of the
Company, in accordance with its terms, have been done. 
 NOW, THEREFORE, in consideration of the foregoing and for other valuable
consideration, the receipt of which is hereby acknowledged, each party hereby agrees, for the equal and ratable benefit of each of the Holders, as follows: 

ARTICLE ONE 
 THE RESIGNING TRUSTEE

 Section 1.1. The Resigning Trustee has previously notified the Issuer that it is resigning, and hereby resigns, as Trustee,
Security Registrar and Paying Agent under the Indenture. 

 Section 1.2. The Resigning Trustee hereby represents and warrants to the Successor
Trustee that: 
 (a) No covenant or condition contained in the Indenture has been waived by the Resigning Trustee, or to the
best of the knowledge of the responsible officers of the Resigning Trustee assigned to its corporate trust department, by the Holders of the percentage in aggregate principal amount of the Notes required by the Indenture to effect any such waiver.

 (b) Except as disclosed in writing prior to the date hereof, there is no action, suit or proceeding pending or, to the
best of the knowledge of the responsible officers of the Resigning Trustee assigned to its corporate trust department, threatened against the Resigning Trustee before any court or governmental authority arising out of any action or omission by the
Resigning Trustee as Trustee under the Indenture. 
 (c) This Instrument has been duly authorized, executed and delivered on
behalf of the Resigning Trustee. 
 (d) As of the date hereof, the Resigning Trustee holds no property or money under the
Indenture. 
 (e) The current principal amount of indebtedness evidenced by the Notes as of the Effective Date is
$2,125,000,000 as listed on the attached Schedule A, all of which have been duly authenticated and delivered. All interest, if any, due and payable on the Securities has been duly paid, or provided for by the Issuer, pursuant to the Indenture. 

(f) To the best knowledge of the responsible officers of the Resigning Trustee assigned to its corporate trust department, the
Resigning Trustee has lawfully discharged its duties as Trustee under the Indenture. 
 (g) To the best knowledge of
responsible officers of the Resigning Trustee’s corporate trust department, no event has occurred and is continuing which is, or after notice or lapse of time would become, an Event of Default under Section 5.1 of the Indenture. 

Section 1.3. Subject to the terms and limitations in this Instrument, the Resigning Trustee hereby assigns, transfers, delivers
and confirms to the Successor Trustee all right, title and interest of the Resigning Trustee in its capacity as Trustee, Security Registrar and Paying Agent under the Indenture in and to the trust under the Indenture, including all the rights,
powers and duties of the Resigning Trustee (except for fees and expenses collected prior to the date hereof) under the Indenture. The Resigning Trustee shall execute and deliver such further instruments and shall do such other things as the
Successor Trustee may reasonably require so as to more fully and certainly vest and confirm in the Successor Trustee all the rights, powers, trusts and duties hereby assigned, transferred, delivered and confirmed to the Successor Trustee. 

  
 2 

 Section 1.4. As of or promptly after the effective date of this Instrument, the
Resigning Trustee shall deliver to the Successor Trustee the items listed on Exhibit A annexed hereto. 
 Section 1.5.
Promptly after the execution and delivery of this Instrument, the Issuer shall, pursuant to Section 6.10(6) of the Indenture, cause a notice, substantially in the form of Exhibit B annexed hereto, to be sent to each Holder of the Notes
in accordance with the Indenture. 
 ARTICLE TWO 

THE ISSUER 

Section 2.1. The Issuer hereby certifies that the Issuer is, and the officer of the Issuer who has executed this Instrument is,
duly authorized to: (a) accept the Resigning Trustee’s resignation as Trustee, Security Registrar and Paying Agent under the Indenture, and (b) appoint the Successor Trustee as Trustee, Security Registrar and Paying Agent under the
Indenture. 
 Section 2.2. The Issuer hereby accepts the resignation of the Resigning Trustee as Trustee, Security Registrar and
Paying Agent under the Indenture. Pursuant to the applicable provisions of the Indenture, the Issuer hereby appoints the Successor Trustee as Trustee, Security Registrar and Paying Agent under the Indenture and confirms to the Successor Trustee all
the rights, powers, trusts and duties of the Resigning Trustee under the Indenture. The Issuer shall execute and deliver such further instruments and shall do such other things as the Successor Trustee may reasonably require so as to more fully and
certainly vest in and confirm to the Successor Trustee all the rights, powers, trusts and duties hereby assigned, transferred, delivered and confirmed to the Successor Trustee. 

Section 2.3. The Issuer hereby represents and warrants to the Successor Trustee that: 

(a) It is a corporation duly incorporated and existing pursuant to the laws of the State of Delaware. 

(b) The Indenture was validly and lawfully executed and delivered by the Issuer and is in full force and effect. The current
outstanding principal amount of the indebtedness evidenced by the Notes is $2,125,000,000 as listed on the attached Schedule A. 

(c) The Indenture and the Notes are binding obligations of the Issuer. 

(d) This Instrument has been duly authorized, executed and delivered on behalf of the Issuer. 

(e) No event has occurred and is continuing which is, or after notice or lapse of time would become, an Event of Default under
Section 5.1 of the Indenture. 
 (f) No covenant or condition contained in the Indenture has been waived by the Issuer
or, to the best of the Issuer’s knowledge, by Holders of the percentage in aggregate principal amount of the Notes required to effect any such waiver. 

  
 3 

 ARTICLE THREE 

THE SUCCESSOR TRUSTEE 

Section 3.1 The Successor Trustee hereby represents and warrants to the Resigning Trustee and the Issuer that: 

(a) The Successor Trustee is eligible and qualified under the Indenture and under the Trust Indenture Act of 1939, as amended,
to act as Trustee under the Indenture. 
 (b) This Instrument has been duly authorized, executed and delivered on behalf of
the Successor Trustee. 
 Section 3.2. Pursuant to Section 6.11(1) of the Indenture, the Successor Trustee hereby accepts
its appointment as Trustee, Security Registrar and Paying Agent under the Indenture and shall hereby be vested with all the rights, powers, trusts and duties of the Resigning Trustee under the Indenture. 

Section 3.3. Notwithstanding this Instrument and the resignation of the Resigning Trustee, the Resigning Trustee shall retain all
rights and entitlements relating to its service as Trustee, Security Registrar and Paying Agent under the Indenture arising or accruing on or before the effective date of this Instrument, including without limitation, all entitlements to the payment
of its fees and reimbursement of its expenses, regardless of when such amounts become payable or are paid. In the event and to the extent the Successor Trustee shall exercise any lien upon the distributions to holders of the Notes or otherwise
becomes entitled to receive payment of funds subject to Section 6.7 and 6.13 of the Indenture, or payment otherwise of any fees and expenses as Trustee under the Indenture for any reason at a time when the Resigning Trustee has not been fully
paid, it shall do so for both its own fees and expenses and the outstanding fees and expenses of the Resigning Trustee, incurred in connection with its duties under the Indenture prior to the effective date of this Instrument, and any subsequent
transitional services requested by the Successor Trustee from the Resigning Trustee after the effective date of this Instrument. The Successor Trustee shall promptly pay over a pro rata portion of any and all such proceeds to the Resigning Trustee
when and as received. To the extent the Resigning Trustee receives funds from the Issuer, other than for payment of the Resigning Trustee’s fees and expenses, it agrees to hold those funds as agent for the Successor Trustee and promptly pay
over such funds to the Successor Trustee. 

  
 4 

 ARTICLE FOUR 

AMENDMENTS TO THE INDENTURE 

Section 4.1. The title page and page 1 of the Indenture shall be amended as follows: 

(a) The title set forth on the cover page of the Indenture is amended in its entirety as follows: 

HOSPIRA, INC. 
 TO 

UNION BANK, NA. 
 Trustee 

 
  

INDENTURE 
 Dated as of
June 14, 2004 
  
  

(b) The first paragraph on page 1 of the Indenture is amended to read in its entirety as follows: 

INDENTURE, dated as June 14, 2004, between Hospira, Inc., a corporation duly organized and existing under the laws of the
State of Delaware (herein called the “Company”), having its principal office at, 275 North Field Drive, Lake Forest, Illinois 60045, and Union Bank, N.A., a national banking association duly organized and existing under the laws of the
United States of America, as Trustee (herein called the “Trustee”). 
 Section 4.2 The first paragraph of
Section 2.3 of the Indenture is amended to read in its entirety as follows: 
 This Security is one of a duly authorized
issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under an Indenture, dated as of June 14, 2004 (herein called the “Indenture”), between the Company and Union
Bank, N.A., as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the respective
rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the
series designated on the face hereof, limited in aggregate principal amount to $        . 

  
 5 

 Section 4.3 The forms of Certificates of Authentication shall be amended as follows:

 (a) With respect to any Securities executed and authenticated after the date of this Supplemental Indenture,
Section 2.5 of the Indenture is amended to read in its entirety as follows: 
 The Trustee’s certificates of authentication shall
be in substantially the following form: 
 This is one of the Securities of the series designated therein referred to in the
within-mentioned Indenture. 
  

			
	UNION BANK, N.A.,
		 	as Trustee
		
	By:	 	  

		 	Name:
		 	Title:

 (b) With respect to any Securities executed and authenticated after the date of this
Supplemental Indenture, the form of alternate certificate of authentication referred to in the final paragraph of Section 6.14 of the Indenture is amended to read as follows: 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture. 

 

			
	UNION BANK, N.A.
		 	AS TRUSTEE
		
	By:	 	  

		 	AS AUTHENTICATION AGENT
		
	By:	 	  

		 	AUTHORIZED SIGNATORY

 Section 4.4 The Trustee eligibility requirements shall be amended as follows: 

(a) Section 6.9 of the Indenture is amended in its entirety to read as follows: 

There shall at all times be a Trustee hereunder which shall be a Person that is eligible pursuant to the Trust Indenture Act to
act as such and has a combined capital and surplus of at least $50,000,000 and its Corporate Trust Office in Chicago, Illinois or New York, New York. If such Person publishes reports of condition at least annually, pursuant to law or to the
requirements of said supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such Person shall be deemed to be its combined 

  
 6 

 
capital and surplus as set forth in its most recent report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, it
shall resign immediately in the manner and with the effect hereinafter specified in this Article. 
 ARTICLE FIVE 

MISCELLANEOUS 

Section 5.1. Except as otherwise expressly provided or unless the context otherwise requires, all capitalized terms used herein
which are defined in the Indenture shall have the meanings assigned to them in the Indenture. 
 Section 5.2. This Instrument
and the resignation, appointment and acceptance effected hereby shall be effective as of the close of business on the date first above written, upon the execution and delivery hereof by each of the parties hereto; provided, however,
that the resignation of the Resigning Trustee as Security Registrar and Paying Agent and appointment of the Successor Trustee as Security Registrar and Paying Agent shall be effective as of the close of business 10 days after the date first written
above, and until such date the Resigning Trustee shall continue to perform its duties under the Indenture. 
 Section 5.3.
Notwithstanding the resignation of the Resigning Trustee effected hereby, the Issuer shall remain obligated under Sections 6.7 and 6.13 of the Indenture to compensate, reimburse and indemnify the Resigning Trustee in connection with its service
under the Indenture as Trustee, Paying Agent, and Security Registrar prior to the effective date of this Instrument to the same extent as if no resignation shall have occurred. The Issuer also acknowledges and reaffirms its obligations to the
Successor Trustee as set forth in Section 6.7 of the Indenture, which obligations to the Successor Trustee shall survive the execution hereof. Successor Trustee does not assume responsibility for or any liability in connection with any
negligence or other willful misconduct or any other act or omission on the part of Resigning Trustee or its agents in connection with such persons’ performance of their respective trusts, duties and obligations under the Indenture. Successor
Trustee does not assume responsibility for or any liability in connection with any negligence or other willful misconduct or any other act or omission on the part of Resigning Trustee or its agents in connection with such persons’ performance
of their respective trusts, duties and obligations under the Indenture. The Resigning Trustee agrees to indemnify and save harmless the Successor Trustee from and against any and all costs, claims, liabilities, losses or damages whatsoever
(including the reasonable fees and disbursements of its counsel) asserted or arising at any time after the date hereof arising out of any action (or failure to act) of the Resigning Trustee prior to the effective date of this Instrument in
connection with its serving as Trustee, Paying Agent or Security Registrar under the Indenture or allegations based upon any such action (or failure to act), which the Successor Trustee may suffer or incur as a result of its accepting appointment
and acting as Trustee, Paying Agent or Security Registrar under the Indenture, including the costs and expenses of the Successor Trustee incurred in defending itself against any such claim or liability in connection with the exercise or performance
of any of its powers or duties hereunder. The Resigning Trustee may take control of the defense and investigation of any claim or third-party claim and to employ and engage attorneys of its own choice to handle and defend the same, at the Resigning
Trustee’s expense; provided; however, that as part of the defense of any claim, the Resigning 

  
 7 

 
Trustee may not settle any such claim without the Successor Trustee’s prior written consent, which consent will not be unreasonably withheld; and the Successor Trustee retains the right to
participate in the defense of any such claim at its expense and through counsel of its choosing. Nothing in this Section 5.3 is intended to or shall affect any limitations on the Prior Trustee’s liability under other provisions of the
Indenture. 
 Section 5.4. This Instrument shall be governed by and construed in accordance with the laws of the state of New
York, without giving effect to the conflict of law provisions thereof to the extent the law of another jurisdiction would apply. 

Section 5.5. Nothing in this Instrument shall impose any duty upon the Resigning Trustee to disclose any communications,
information or materials subject to the attorney client privilege, work product doctrine or any confidentiality agreement to the Successor Trustee or any other person or entity. 

Section 5.6. This Instrument may be executed in any number of counterparts each of which shall be an original, but such
counterparts shall together constitute but one and the same instrument. 
 [Signature page follows.] 

  
 8 

 IN WITNESS WHEREOF, the parties hereto have caused this Second Supplemental Indenture to be duly
executed as of the date first written above. 
  

					
	HOSPIRA, INC.
		
	By:	 	 /s/ Lori O. Carlson

		 	Name:	 	Lori O. Carlson
		 	Title:	 	Corporate Vice President and Treasurer
	
	UNION BANK, N.A., as Trustee
		
	By:	 	 /s/ Hugo Gindraux

		 	Name:	 	Hugo Gindraux
		 	Title:	 	Vice President
	
	BANK OF AMERICA, N.A. AS SUCCESSOR BY MERGER TO LASALLE BANK NATIONAL ASSOCIATION, as Resigning Trustee
		
	By:	 	 /s/ Margaret M. Muir

		 	Name:	 	Margaret M. Muir
		 	Title:	 	Vice President

  
 9 

 EXHIBIT A 

Documents to be delivered to the Successor Trustee: 
  

	1.	Executed copy of the Indenture and any supplemental indentures. 

  

	2.	File of closing documents from each issuance. 

  

	3.	Available trust account statements for a one year period preceding the date of this Instrument. 

  

	4.	Copies of any official notices sent by the Trustee to all the Holders of the Notes pursuant to the terms of the Indenture during the past three years. 

 

	5.	Such other nonconfidential, unprivileged documents currently in the possession of the Resigning Trustee, as the Successor Trustee may request in order to transfer the appointment to it. 

 

	6.	The Global Notes in the possession of the Trustee. 

  

	7.	Custodian Agreement with The Depository Trust Company, if any. 

 EXHIBIT B 

[Hospira Letterhead] 
 NOTICE 

To the Holders of Hospira, Inc.’s     % Notes due
                    : 
 NOTICE IS HEREBY GIVEN,
pursuant to Section 6.10(6) of the indenture, dated as of June 14, 2004 (the “Indenture”), by and between Hospira, Inc. (the “Issuer”), and Bank of America, N.A. as successor by merger to LaSalle Bank National
Association (“LaSalle”), as Trustee, that LaSalle has resigned as Trustee under the Indenture. 
 Pursuant to Section 6.10 of the Indenture,
the Issuer has appointed Union Bank, N.A. (“Union Bank”), a national banking association, as successor Trustee under the Indenture, which appointment has been accepted and has become effective. The address of the Corporate Trust Office of
Union Bank is 551 Madison Avenue, 11th Floor, New York, New York 10022 Attn: Corporate Trust Department. 

Dated: April 30, 2009 
 Hospira, Inc. 

 SCHEDULE A 
  

																									
	 CUSIP
	  	Original
Principal Balance	 	  	Principal
Balance as
Of April 30,
2009	 	  	Rate	 	 	Issue Date	 	  	Last Interest Payment	 	  	Maturity Date	 
	 441060-AG-5
	  	 	375,000,000	  	  	 	375,000,000	  	  	 	LIBOR + 48 bps	  	 	 	March 23, 2007	  	  	 	March 30, 2009	  	  	 	March 30, 2010	  
	 441060-AH-3
	  	 	500,000,000	  	  	 	500,000,000	  	  	 	5.55	% 	 	 	March 23, 2007	  	  	 	March 30, 2009	  	  	 	March 30, 2012	  
	 441060-AJ-9
	  	 	550,000,000	  	  	 	550,000,000	  	  	 	6.05	% 	 	 	March 23, 2007	  	  	 	March 30, 2009	  	  	 	March 30, 2017	  
	 441060-AB-6
	  	 	300,000,000	  	  	 	300,000,000	  	  	 	4.95	% 	 	 	June 14, 2004	  	  	 	December 15, 2008	  	  	 	June 15, 2009	  
	 441060-AD-2
	  	 	400,000,000	  	  	 	400,000,000	  	  	 	5.90	% 	 	 	June 14, 2004	  	  	 	December 15, 2008	  	  	 	June 15, 2014EX-4.4

 Exhibit 4.4 

THIRD SUPPLEMENTAL INDENTURE 

Dated as of October [    ], 2015 

Between 
 HOSPIRA, INC.,

 and 
 UNION
BANK, N.A., 
 As Trustee 
  

 
 Providing for
an Amendment to the Indenture dated as of June 14, 2004 
  

 
 6.05% Notes
due 2017 
 5.20% Notes due 2020 

5.80% Notes due 2023 

5.60% Notes due 2040 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	ARTICLE 1 DEFINITIONS	  	 	2	  
	 Section 1.1
	 	 Definitions
	  	 	2	  
		
	ARTICLE 2 AMENDMENTS	  	 	2	  
	 Section 2.1
	 	 Certain Amendments to the Indenture and the Notes.
	  	 	2	  
		
	ARTICLE 3 AMENDMENTS TO THE NOTES	  	 	3	  
		
	ARTICLE 4 MISCELLANEOUS	  	 	3	  
	 Section 4.1
	 	 Relation to Original Indenture.
	  	 	3	  
	 Section 4.2
	 	 Governing Law.
	  	 	3	  
	 Section 4.3
	 	 Concerning the Trustee.
	  	 	4	  
	 Section 4.4
	 	 Successors.
	  	 	4	  
	 Section 4.5
	 	 Severability.
	  	 	4	  
	 Section 4.6
	 	 Counterparts.
	  	 	4	  
	 Section 4.7
	 	 Effect of Headings.
	  	 	4	  
	 Section 4.8
	 	 Entire Agreement.
	  	 	4	  
	 Section 4.9
	 	 Benefits of Third Supplemental Indenture.
	  	 	4	  

  
 i 

 THIRD SUPPLEMENTAL INDENTURE 

THIS THIRD SUPPLEMENTAL INDENTURE (this “Third Supplemental Indenture”) is entered into as of October [    ], 2015,
between HOSPIRA, INC., a corporation duly organized and existing under the laws of the State of Delaware (the “Company”), having its principal office at 235 East 42nd Street, New York, New York 10017-5755, and UNION BANK, N.A., a
national banking association duly organized and existing under the laws of the United States of America, having its corporate trust office at 551 Madison Avenue, 11th Floor, New York, New York
10022, as trustee (the “Trustee”). 
 WHEREAS, the Company and the Trustee are parties to that certain Indenture, dated as of June 14,
2004 (the “Base Indenture”), by and between the Company and LaSalle Bank National Association (the “Resigning Trustee”), as trustee, as supplemented by the Second Supplemental Indenture, dated as of April 30,
2009 (the “Second Supplemental Indenture”), between the Company, the Trustee, and Bank of America, N.A., as successor by merger to the Resigning Trustee, relating to the Company’s Securities; 

WHEREAS, pursuant to Section 3.1 of the Base Indenture, the Company and the Trustee established the terms of certain series of unsecured debt securities
entitled the (i) “6.05% Notes due 2017” (the “2017 Notes”) pursuant to the Actions of the Authorized Officers dated March 20, 2007 (“Officers’ Certificate 1”), (ii) “5.20% Notes
due 2020” (the “2020 Notes”) pursuant to the Actions of the Authorized Officers dated August 7, 2013 (“Officers’ Certificate 2”), (iii) “5.80% Notes due 2023” (the “2023
Notes”) pursuant to the Actions of the Authorized Officers dated August 7, 2013 (“Officers’ Certificate 3”) and (iv) “5.60% Notes due 2040” (the “2040 Notes” and, together with the
2017 Notes, the 2020 Notes and the 2023 Notes, the “Notes”) pursuant to the Actions of the Authorized Officers dated September 7, 2010 (“Officers’ Certificate 4” and, together with Officers’
Certificate 1, Officers’ Certificate 2 and Officers’ Certificate 3, the “Officers’ Certificates” and, together with the Base Indenture and the Second Supplemental Indenture, the “Indenture”); 

WHEREAS, Section 9.2 of the Base Indenture provides that the Company and the Trustee may enter into a supplemental indenture to the Base Indenture for
the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of the Base Indenture or of modifying in any manner the rights of the Holders of Securities of a series issued under the Base Indenture with the
consent of the holders of not less than a majority in principal amount of the Outstanding Securities of each series affected by such supplemental indenture; 

WHEREAS, Pfizer Inc., a Delaware corporation (“Pfizer”) has offered to exchange (the “Pfizer Exchange Offers”) any and all
of the outstanding 2017 Notes for new 6.05% Notes due March 30, 2017 of Pfizer (the “Pfizer 2017 Notes”), any and all of the outstanding 2020 Notes for new 5.20% Notes due August 12, 2020 of Pfizer (the “Pfizer
2020 Notes”), any and all of the outstanding 2023 Notes for new 5.80% Notes due August 12, 2023 of Pfizer (the “Pfizer 2023 Notes”) and any and all of the outstanding 2040 Notes for new 5.60% Notes due
September 15, 2040 of Pfizer (the “Pfizer 2040 Notes” and together with the Pfizer 2017 Notes, the Pfizer 2020 Notes and the Pfizer 2023 Notes, the “Pfizer Notes”), upon the terms and subject to the conditions set
forth in the prospectus, dated as of [                ], 2015 (the “Prospectus”), filed with the Securities and Exchange Commission pursuant to Rule
424(b) under the Securities Act of 1933, as amended, and Pfizer’s Registration Statement on Form S-4 (File No. 333-[    ]), filed with the Securities and Exchange Commission (the “SEC”) on
September 3, 2015; 
 WHEREAS, in connection with the Pfizer Exchange Offers, Pfizer has also solicited consents from the holders of the Notes to
certain proposed amendments (the “Proposed Amendments”) to the Indenture with respect to each series of Notes as described in the Prospectus and set forth in Section 2.1 of this Third Supplemental Indenture, with the operation
of such Proposed Amendments with respect to a series of Notes being subject to the satisfaction or waiver, where permissible, by Pfizer of the conditions to the Pfizer Exchange Offers, the acceptance by Pfizer for exchange of the Notes of such
series validly tendered and not validly withdrawn pursuant to the Pfizer Exchange Offers and the issuance of the Pfizer Notes and payment of the cash consideration payable pursuant to the Pfizer Exchange Offers; 

WHEREAS, Pfizer has received and caused to be delivered to the Trustee evidence of the consents from holders of a majority in principal amount of the
Outstanding Securities of each series of the Notes to effect the Proposed Amendments under the Indenture with respect to each series of Notes; 

  
 1 

 WHEREAS, the Company is undertaking to execute and deliver this Third Supplemental Indenture to delete or amend,
as applicable, certain provisions and covenants in the Indenture with respect to each series of Notes in connection with the Pfizer Exchange Offers and the related consent solicitations; 

WHEREAS, the board of directors of the Company has authorized and approved the execution and delivery of this Third Supplemental Indenture; and 

WHEREAS, following the execution of this Third Supplemental Indenture, the terms hereof will become operative (the “Operative Date”) upon the
satisfaction or waiver, where permissible, by Pfizer of the conditions to the Pfizer Exchange Offers, the acceptance by Pfizer for exchange of the Notes of such series validly tendered and not validly withdrawn pursuant to the Pfizer Exchange Offers
and the issuance of the Pfizer Notes and payment of the cash consideration payable pursuant to the Pfizer Exchange Offers, on the settlement date of the Pfizer Exchange Offers. 

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged,
and for the equal and proportionate benefit of the holders of the Notes, the Company and the Trustee hereby agree as follows: 

ARTICLE 1 

DEFINITIONS 
 Section 1.1
Definitions. 
 Capitalized terms used in this Third Supplemental Indenture and not otherwise defined herein shall have the meanings assigned to such
terms in the Base Indenture. 
 ARTICLE 2 

AMENDMENTS 
 Section 2.1
Certain Amendments to the Indenture and the Notes. 
 The Indenture with respect to each series of Notes is hereby amended as follows: 

(a) Section 7.4 (Reports by Company); Section 8.1 (Company May Consolidate, Etc., Only on Certain Terms); Section 10.5 (Existence);
Section 10.6 (Maintenance of Properties); Section 10.7 (Payment of Taxes and other Claims); Section 10.8 (Restrictions on Secured Debt); and Section 10.9 (Limitations on Sales and Leasebacks) of the Base Indenture shall be
deleted in their entirety and replaced with “RESERVED”; 
 (b) Paragraph (p) of each Officers’ Certificate relating to Change of Control
is hereby deleted in their entirety and replaced with “RESERVED”; 
 (c) The failure to comply with the terms of any of the Sections of the Base
Indenture and the Note certificates set forth in clauses (a) and (b) above shall no longer constitute a Default or Event of Default under the Indenture with respect to the applicable series of Notes and shall no longer have any consequence
under the Indenture with respect to such series of Notes; 
 (d) Section 5.1 of the Base Indenture (Events of Default) is hereby amended by replacing
paragraphs (1) and (5) as shown below: 
 (1) default in the payment of any interest upon any Security of that series when it
becomes due and payable, and continuance of such default for a period of 60 days; provided however, that if the Company is permitted by the terms of the Securities of such series to defer the payment in question, the date on which such payment
is due and payable shall be the date on which the Company is required to make payment following such deferral, if such deferral has been elected pursuant to the terms of the Securities; or 

(5) the entry by a court having jurisdiction in the premises of (A) a decree or order for relief in respect of the Company in an
involuntary case or proceeding under any applicable Federal or State bankruptcy, insolvency, reorganization or other similar law or (B) a decree or order adjudging the Company bankrupt or insolvent, or approving as properly filed a petition
seeking reorganization, arrangement, adjustment or composition of or in respect of the Company under any applicable Federal or State law, or appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of
the Company or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree or order for relief or any such other decree or order unstayed and in effect for a period of
90 consecutive days; or 

  
 2 

 (e) Section 10.4 of the Base Indenture (Statement by Officers As to Default) is hereby amended as shown
below: 
 The Company will deliver to the Trustee, on or before June 1 of each calendar year or on or before such other day in
each calendar year as the Company and the Trustee may from time to time agree upon, an Officers’ Certificate, stating whether or not to the best knowledge of the signers thereof the Company is in default in the performance and
observance of any of the terms, provisions and conditions of this Indenture (without regard to any period of grace or requirement of notice provided hereunder) and, if the Company shall be in default, specifying all such defaults and the nature and
status thereof of which they may have knowledge. 
 (f) all definitions set forth in Section 1.1 of the Base Indenture that relate to defined terms
used solely in sections that are no longer applicable to any series of Notes are also no longer applicable to such Notes; 
 (g) all references to Sections
of the Indenture amended by this Third Supplemental Indenture shall be to such Sections as amended by this Third Supplemental Indenture. 

ARTICLE 3 
 AMENDMENTS
TO THE NOTES 
 The Notes include certain of the foregoing provisions from the Indenture and each Officers’ Certificate to be
deleted or amended pursuant to Article 2 hereof. Upon the Operative Date, such provisions from the Notes shall be deleted or amended as applicable. 

ARTICLE 4 

MISCELLANEOUS 
 Section 4.1
Relation to Original Indenture; Effectiveness; and Operation. 
 This Third Supplemental Indenture supplements the Indenture and shall be a part of
and subject to all the terms thereof. Except as supplemented hereby, all of the terms, provisions and conditions of the Indenture and the Notes issued thereunder shall continue in full force and effect. In the event of a conflict between the terms
and conditions of the Indenture and the terms and conditions of this Third Supplemental Indenture, then the terms and conditions of this Third Supplemental Indenture shall prevail. 

Upon the execution and delivery of this Third Supplemental Indenture, this Third Supplemental Indenture shall be effective. The amendments set forth in
Article 2 and Article 3 of this Third Supplemental Indenture shall not become operative, however, until the Operative Date. 
 Section 4.2 Governing
Law. 
 THIS THIRD SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO
CONFLICTS OF LAW PRINCIPLES. EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS THIRD
SUPPLEMENTAL INDENTURE, THE INDENTURE OR THE NOTES. 

  
 3 

 Section 4.3 Concerning the Trustee. 

The Trustee accepts the amendments of the Indenture effected by this Third Supplemental Indenture, but on the terms and conditions set forth in the Indenture,
including the terms and provisions defining and limiting the liabilities and responsibilities of the Trustee. Without limiting the generality of the foregoing, the Trustee shall not be responsible in any manner whatsoever for or with respect to any
of the recitals or statements contained herein, all of which recitals or statements are made solely by the Company, or for or with respect to (i) the validity or sufficiency of this Third Supplemental Indenture or any of the terms or provisions
hereof, (ii) the proper authorization hereof by the Company by action or otherwise, (iii) the due execution hereof by the Company or (iv) the consequences of any amendment herein provided for, and the Trustee makes no representation
with respect to any such matters. 
 Section 4.4 Successors. 

All agreements of the Company in this Third Supplemental Indenture shall bind the Company’s successors. All agreements of the Trustee in this Third
Supplemental Indenture shall bind the Trustee’s successors. 
 Section 4.5 Severability. 

In case any provision in this Third Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the
remaining provisions shall not (to the fullest extent permitted by applicable law) in any way be affected or impaired thereby. 
 Section 4.6
Counterparts. 
 This Third Supplemental Indenture may be executed in counterparts, each of which shall be deemed an original, but all of which shall
together constitute one and the same instrument. The exchange of copies of the Third Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Third Supplemental
Indenture as to the parties hereto and may be used in lieu of the original Third Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all
purposes. 
 Section 4.7 Effect of Headings. 
 The
Article and Section headings herein are for convenience of reference only and shall not affect the construction hereof. 
 Section 4.8 Entire
Agreement. 
 This Third Supplemental Indenture, together with the Indenture as amended hereby and the Notes, contains the entire agreement of the
parties with respect to the Notes, and supersedes all other representations, warranties, agreements and understandings between the parties hereto and thereto, oral or otherwise, with respect to the matters contained herein and therein. 

Section 4.9 Benefits of Third Supplemental Indenture. 

Nothing in this Third Supplemental Indenture, the Indenture or the Notes, express or implied, shall give to any Person, other than the parties hereto and
thereto and their successors hereunder and thereunder, any Paying Agent, any Security Registrar and the holders of the Notes, any benefit of any legal or equitable right, remedy or claim under the Indenture, this Third Supplemental Indenture or the
Notes. 
 [signature page follows] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental Indenture to be duly executed as of
the day and year first above written. 
  

			
	HOSPIRA, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	UNION BANK, N.A., as Trustee
		
	By:	 	  

	Name:	 	
	Title:	 	

 [Signature Page to Third Supplemental Indenture]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]